H. Lundbeck A/S

Denmark · owned by LUNDBECKFONDEN (Denmark) · lundbeck.com · 19 vendors

H. Lundbeck A/S is a Danish multinational pharmaceutical company specializing in the research, development, and commercialization of drugs for brain diseases, including psychiatric and neurological disorders. The company focuses on conditions such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and migraine. It is listed on the Nasdaq Copenhagen stock exchange and operates globally.

Resilience scores

Technology vendors

Insights

Last updated 2026-09-13 · revision 2

19 direct vendors, 262 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 5/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

Lundbeck, as a large, established pharmaceutical company, likely operates with a mixed technology landscape. This typically includes significant legacy on-premise systems for core operations (e.g., manufacturing, R&D, clinical trials) due to regulatory requirements and specialized software. While there's likely ongoing adoption of cloud services for new initiatives, data analytics, and specific applications, a full cloud-native, microservices architecture across the entire enterprise is improbable. Vendor lock-in with specialized pharmaceutical software is also common. This suggests a moderate level of migration readiness. (Confidence: Medium, Source: General industry knowledge for large pharmaceutical companies, lack of specific public tech stack details)

Financials

Three-year financials

Financial Resilience Score: 6/10

Lundbeck is a specialized pharmaceutical company focused exclusively on brain diseases, including psychiatric and neurological disorders. This narrow therapeutic focus provides deep expertise and a defensible niche but also concentrates risk significantly compared to diversified pharma peers. The company has a long operating history and is majority-owned by the Lundbeck Foundation, providing a degree of strategic stability and long-term orientation that insulates it from short-term shareholder pressure. The company's financial resilience is supported by a portfolio of established CNS brands and a pipeline of newer products such as Vyepti (eptinezumab) for migraine and Rexulti (brexpiprazole), which provide growth vectors. However, Lundbeck faces ongoing patent cliff risks as older products lose exclusivity, and the CNS drug development space carries high clinical and regulatory risk with historically low success rates. Research and development investment is a core commitment for Lundbeck, which is both a strength (pipeline replenishment) and a risk (high cash burn with uncertain returns). The company operates globally with a presence in major pharmaceutical markets, but its scale is modest relative to large-cap peers, limiting its ability to absorb major setbacks. Overall, the financial resilience is moderate — supported by a stable ownership structure and niche expertise, but constrained by pipeline dependency and patent exposure.

Key strengths: Majority ownership by the Lundbeck Foundation provides long-term strategic stability, Specialized CNS focus creates deep therapeutic expertise and defensible market position, Growing newer products (Vyepti, Rexulti) provide revenue diversification within the portfolio, Global commercial presence across major pharmaceutical markets, Long operating history in a high-barrier specialty pharmaceutical segment

Risk factors: Narrow therapeutic focus concentrates risk entirely within CNS/brain disease segment, Patent cliff exposure on older branded products threatens revenue base, High R&D spend with inherently uncertain pipeline outcomes in CNS drug development, Modest scale relative to large-cap pharma limits capacity to absorb major setbacks, CNS drug development has historically low clinical success rates, increasing pipeline risk

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report